{"id":1434,"date":"1999-10-01T12:10:00","date_gmt":"1999-10-01T10:10:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/1999\/primaere-und-sekundaere-praevention-der-koronaren-herzkrankheit-was-koennen-wir-uns-leisten"},"modified":"1999-10-01T12:10:00","modified_gmt":"1999-10-01T10:10:00","slug":"primaere-und-sekundaere-praevention-der-koronaren-herzkrankheit-was-koennen-wir-uns-leisten","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/1999\/primaere-und-sekundaere-praevention-der-koronaren-herzkrankheit-was-koennen-wir-uns-leisten","title":{"rendered":"Prim\u00e4re und sekund\u00e4re Pr\u00e4vention der Koronaren Herzkrankheit: Was k\u00f6nnen wir uns leisten?"},"content":{"rendered":"<p>Zu diesem Thema fand sich eine sehr lesenswerte und provokante Betrachtung in der Zeitschrift f\u00fcr Kardiologie (K\u00fcbler, W., und Kreuzer, J.: 1999, 88, 85). Die Autoren analysieren die Untersuchungen zur Kosteneffizienz der prim\u00e4ren und sekund\u00e4ren Prophylaxe der Koronaren Herzkrankheit mit Beta-Blockern, Azetylsalizyls\u00e4ure, speziell aber Statinen. Alle diese Therapien sind wirksam. Sie reduzieren die Wahrscheinlichkeit, da\u00df [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Zu diesem Thema fand sich eine sehr lesenswerte und provokante Betrachtung in der Zeitschrift f\u00fcr Kardiologie (K\u00fcbler, W., und Kreuzer, J.: 1999, 88, 85). Die Autoren analysieren die Untersuchungen zur Kosteneffizienz der prim\u00e4ren und sekund\u00e4ren Prophylaxe der Koronaren Herzkrankheit mit Beta-Blockern, Azetylsalizyls\u00e4ure, speziell aber Statinen. Alle diese Therapien sind wirksam. Sie reduzieren die Wahrscheinlichkeit, da\u00df [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[495,1046,451,449,1166,71,455,453,498,456,454,65,801,505,443],"class_list":["post-1434","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-angina-pectoris","tag-atorvastatin","tag-cholesterinsynthese-hemmer","tag-cse-hemmer","tag-fluvastatin","tag-herzinfarkt","tag-hmg-coa-reduktase-hemmer","tag-hypercholesterinaemie","tag-koronare-herzkrankheit","tag-lipidsenker","tag-lovastatin","tag-myokardinfarkt","tag-pravastatin","tag-simvastatin","tag-statine"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1434","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=1434"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1434\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=1434"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=1434"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=1434"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}